Migraine
NEJM 377:553-561, Charles, A., 2017
Neurologic Disorders in Renal Failure (1st of Two Parts)
NEJM 294:143, Raskin,N.H.,et al, 1976
Comparative Effects of Drug Interventions for the Acute Management of Migraine Episodes in Adults:Systematic Review and Network Meta-Analysis
BMJ 386:e080107, Karlsson,W.K.,et al, 2024
Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine, A Phase 4, Randomized, Placebo-Controlled Trial
JAMA Neurol 81:1140-1149, Tepper,S.J.,et al, 2024
Atogepant for the Preventive Treatment of Chronic Migraine (PROGRESS): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial
Lancet 402:775-785, Pozo-Rosich,P.,et al, 2023
Acute Treatment for Migraine
JAMA 325:2346-2347, Burch, R. & Rayhill, M., 2021
Atogepant for the Preventive Treatment of Migraine
NEJM 385:695-706, Ailani,J.,et al, 2021
One-Year Sustained Efficacy of Erenumab in Episodic Migraine
Neurol 95:e469-e479, Goadsby, P.J.,et al, 2020
Migraine
NEJM 383:1866-1876, Ashina, M., 2020
Migraine, hearing loss, and blurred vision in a young woman
Neurol 95:e2945-e2950, Sasikumar, S.,et al, 2020
Cyclic Vomiting Syndrome in Children
AJGH 2:doi:10.33552/AJGH.2020, Al-Ansari, N., 2020
Encephalopathy in a Large Cohort of British Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy Patients
Stroke 50:283-290, Drazyk, A.M.,et al, 2019
A Woman in her 40s with Transient Neurological Symptoms, Migraine Headaches, and Hearing Loss
JAMA Neurol 76:504-505, Roshal, D.A.,et al, 2019
Erenumab in Chronic Migraine
Neurol 92:e2250-e2260, Lipton, R.B.,et al, 2019
Antiepileptic Drug Treatment Patterns in Women of Childbearing Age with Epilepsy
JAMA Neurol 76:783-790, Kim, H.,et al, 2019
Remigepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine
NEJM 381:142-149, Lipton, R.B.,et al, 2019
Vestibular Migraine
BMJ 366:L4213, Li, V.,et al, 2019
Treatment Effects and Comorbid Diseases in 58 Patients with Visual Snow
Neurol 93:e398-e403, vanDongen, R.M.,et al, 2019
Acute Treatment of Migraine in Children and Adolescents
Neurol 93:487-499, Oskoui, M.,et al, 2019
Pharmacologic Treatment for Pediatric Migraine Prevention
Neurol 93:500-509, Oskoui, M.,et al, 2019
Fremanezumab versus Placebo for Migraine Prevention in Patients with Documented Failure to Up to Four Migraine Preventive Medication Classes (FOCUS): A Randomised, Double-Blind, Placebo-Controlled, Phase 3� Trial
Lancet 394:1030-1040, Ferrari, M.D.,et al, 2019
Acute Vestibular Migraine Treatment with Noninvasive Vagus Nerve Stimulation
Neurol 93:e1715-e1719, Beh, S.C. & Friedman, D.I., 2019
Targeting Calcitonin Gene-Related Peptide: A New Era in Migraine Therapy
Lancet 394:1765-1774, Charles, A. & Pozo-Rosich, P., 2019
Ubrogepant for the Treatment of Migraine
NEJM 381:2230-2241, Dodick, D.W.,et al, 2019
Abdominal Migraine
BMJ 360;k179, Angus-Leppan, H.,et al, 2018
Noninvasive Vagus Nerve Stimulation as Acute Therapy for Migraine
Neurol 91:e364-e373, Tassorelli,C., et al, 2018
Preventive Migraine Drug Approved
JAMA 320:1746, , 2018
Efficacy and Tolerability of Erenumab in Patients with Episodic Migraine in Whom Two-of-Four Previous Preventive Treatments were Unsuccessful: A Randomised, Double-Blind, Placebo-Controlled, Phase 3b Study
Lancet 392:2280-2287,2241, Reuter, U.,et al, 2018
Galcanezumab in Chronic Migraine
Neurol 91:e2211-e2221, Detke, H.C.,et al, 2018
Lasmiditan is an Effective Acute Treatment for Migraine
Neurol 91:e2222-e2232, Kuca, B.,et al, 2018
Intravenous Immune Globulin: Adverse Effects
UptoDate June, Perez, E.E. & Silvergleid, A.J., 2017
CGRP - The Next Frontier for Migraine
NEJM 377:2190-2191, Hershey, A.D., 2017
Practice Guideline Update Summary: Botulinum Neurotoxin for the Treatment of Blepharospasm, Cervical Dystonia, Adult Spasticity, and Headache
Neurol 86:1818-1826, Simpson, D.M.,et al, 2016
Chronic Migraine Headache Prevention with Noninvasive Vagus Nerve Stimulation
Neurol 87:529-538, Silberstein, S.D.,et al, 2016
Trial of Amitriptyline, Topiramate, and Placebo for Pediatric Migraine
NEJM 376:115-124, Powers, S.W.,et al, 2016
Evidence-Based Treatments for Adults with Migraine
Pain Reser Treat 2015:DOI:10.1155/2015/629382, Gooriah, R.,et al, 2015
Chronic Migraine
BMJ 348:g141b, Schwedt, T.J., 2014
Triptans for Symptomatic Treatment of Migraine Headache
BMJ 348:g2285, Pringsheim, T. & Becker, W.J., 2014
Stroke-Like Migraine Attacks after Radiation Therapy (SMART) Syndrome is not Always Completely Reversible: A Case Series
AJNR 34:2298-2303, Black, D.F.,et al, 2013
SMART Syndrome (Stroke-Like Migraine Attacks After Radiation Therapy) in Adult and Pediatric Patients
J Child Neurol 29:336-341, Armstrong, A.E.,et al, 2013
Evidence-based Guideline Update: NSAIDs and Other Complementary Treatments for Episodic Migraine Prevention in Adults
Neurol 78:1346-1353, Holland,S.,et al, 2012
Evidence-based Guideline Update: Pharmacologic Treatment for Episodic Migraine Prevention in Adults
Neurol 78:1337-1345, Silberstein,S.D.,et al, 2012
Botulinum Toxin A for Prophylactic Treatment of Migraine and Tension Headaches in Adults
JAMA 307:1736-1745, Jackson,J.L.,et al, 2012
Comorbidity of Migraine in Children Presenting with Epilepsy to a Tertiary Care Center
Neurol 79:468-473, Kelly, S.A.,et al, 2012
Transition to Adult Care for Children with Chronic Neurological Disorders
Ann Neurol 69:437-444, Camfiled, P. & Camfield, C., 2011
Presentation, Diagnosis, Pathophysiology, and Treatment of the Neurological Features of Sturge-Weber Syndrome
The Neurologist 17:179-184, Comi, A.M., 2011
Reversible Cerebral Vasoconstruction Syndromes
Arch Neurol 68:1005-1012,976, Singhal, A.B.,et al, 2011
OnabotulinumtoxinA Improves Quality of Life and Reduces Impact of Chronic Migraine
Neurol 77:1465-1472, Lipton, R.B.,et al, 2011
Intravenous Dihydroergotamine for Inpatient Management of Refractory Primary Headaches
Neurol 77:1827-1832, Nagy, A.J.,et al, 2011